These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26224718)

  • 1. Renal denervation for the treatment of resistant hypertension: review and clinical perspective.
    Iliescu R; Lohmeier TE; Tudorancea I; Laffin L; Bakris GL
    Am J Physiol Renal Physiol; 2015 Oct; 309(7):F583-94. PubMed ID: 26224718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
    Kario K; Bhatt DL; Brar S; Cohen SA; Fahy M; Bakris GL
    Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?
    Epstein M; de Marchena E
    J Am Soc Hypertens; 2015 Feb; 9(2):140-9. PubMed ID: 25649995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal denervation for hypertension: observations and predictions of a founder.
    Esler M
    Eur Heart J; 2014 May; 35(18):1178-85. PubMed ID: 24598982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal denervation for treatment of drug-resistant hypertension.
    Esler M
    Trends Cardiovasc Med; 2015 Feb; 25(2):107-15. PubMed ID: 25467242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Position paper on the results of Symplicity HTN-3 trial. Grupo de estudio de la hipertensión arterial resistente].
    Azpiri-López JR; Assad-Morell JL; Ponce de León-Martínez E; Monreal-Puente R; Dávila-Bortoni A; Vázquez-Díaz LA; Treviño-Frutos RJ; Barrera-Oranday F; Del Angel-Soto JG; Martínez JG; Arellano-Torres M
    Arch Cardiol Mex; 2015; 85(2):154-7. PubMed ID: 25700579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
    Bakris GL; Townsend RR; Liu M; Cohen SA; D'Agostino R; Flack JM; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2014 Sep; 64(11):1071-8. PubMed ID: 24858423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.
    Esler M
    J Am Soc Hypertens; 2014 Aug; 8(8):593-8. PubMed ID: 25151320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal denervation for resistant hypertension and beyond.
    Laffin LJ; Bakris GL
    Adv Chronic Kidney Dis; 2015 Mar; 22(2):133-9. PubMed ID: 25704350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Sympathetic Denervation: Hibernation or Resurrection?
    Papademetriou V; Doumas M; Tsioufis C
    Cardiology; 2016; 135(2):87-97. PubMed ID: 27287994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Denervation After SYMPLICITY HTN-3: Where Do We Go?
    Briasoulis A; Bakris G
    Can J Cardiol; 2015 May; 31(5):642-8. PubMed ID: 25828371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal denervation in the management of resistant hypertension: current evidence and perspectives.
    Jin Y; Persu A; Staessen JA
    Curr Opin Nephrol Hypertens; 2013 Sep; 22(5):511-8. PubMed ID: 23892701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.
    Persu A; Kjeldsen S; Staessen JA; Azizi M
    Curr Hypertens Rep; 2016 Jan; 18(1):6. PubMed ID: 26739586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment].
    Mahfoud F; Vonend O; Bruck H; Clasen W; Eckert S; Frye B; Haller H; Hausberg M; Hoppe UC; Hoyer J; Hahn K; Keller T; Krämer BK; Kreutz R; Potthoff SA; Reinecke H; Schmieder R; Schwenger V; Kintscher U; Böhm M; Rump LC;
    Dtsch Med Wochenschr; 2011 Nov; 136(47):2418. PubMed ID: 22048949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications.
    Kandzari DE; Kario K; Mahfoud F; Cohen SA; Pilcher G; Pocock S; Townsend R; Weber MA; Böhm M
    Am Heart J; 2016 Jan; 171(1):82-91. PubMed ID: 26699604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension.
    Desch S; Okon T; Heinemann D; Kulle K; Röhnert K; Sonnabend M; Petzold M; Müller U; Schuler G; Eitel I; Thiele H; Lurz P
    Hypertension; 2015 Jun; 65(6):1202-8. PubMed ID: 25824248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Denervation: a Field in Flux.
    Laffin LJ; Bakris GL
    Curr Hypertens Rep; 2016 Jul; 18(7):56. PubMed ID: 27245681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous renal sympathetic denervation: 2013 and beyond.
    Froeschl M; Hadziomerovic A; Ruzicka M
    Can J Cardiol; 2014 Jan; 30(1):64-74. PubMed ID: 24365191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal denervation: a new therapeutic approach for resistant hypertension.
    Cao L; Fu Q; Wang B; Li Z
    Chin Med J (Engl); 2014; 127(18):3302-8. PubMed ID: 25266531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal denervation in treatment-resistant hypertension: a reappraisal.
    Persu A; Jin Y; Fadl Elmula FE; Renkin J; Høieggen A; Kjeldsen SE; Staessen JA
    Curr Opin Pharmacol; 2015 Apr; 21():48-52. PubMed ID: 25601357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.